Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia

被引：0
|
作者：
Gregory R. Mullen
Steven A. Kaplan
机构：
[1] Icahn School of Medicine at Mount Sinai,
来源：
Current Urology Reports | 2021年 / 22卷
关键词：
Urinary bladder; Overactive; Prostatic hyperplasia; Lower urinary tract symptoms; Mirabegron;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
    Makhani, Asad
    Thake, Miriam
    Gibson, William
    CLINICAL INTERVENTIONS IN AGING, 2020, 15 : 575 - 581
  • [22] Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
    Casabe, Adolfo
    Roehrborn, Claus G.
    Da Pozzo, Luigi F.
    Zepeda, Sebastian
    Henderson, R. Jonathan
    Sorsaburu, Sebastian
    Henneges, Carsten
    Wong, David G.
    Viktrup, Lars
    JOURNAL OF UROLOGY, 2014, 191 (03) : 727 - 733
  • [23] Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study)
    Yamanishi, Tomonori
    Asakura, Hirotaka
    Seki, Narihito
    Tokunaga, Shoji
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (07) : 525 - 531
  • [24] Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
    Yoshida, Masaki
    Kudoh, Junzo
    Homma, Yukio
    Kawabe, Kazuki
    CLINICAL INTERVENTIONS IN AGING, 2011, 6 : 161 - 172
  • [25] Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement
    Wada, Naoki
    Matsumoto, Seiji
    Kita, Masafumi
    Hashizume, Kazumi
    Kakizaki, Hidehiro
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2015, 7 (01) : 37 - 41
  • [26] Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder
    Wang, Jipeng
    Zhou, Zhongbao
    Cui, Yuanshan
    Li, Yongwei
    Yuan, Hejia
    Gao, Zhenli
    Zhu, Zhe
    Wu, Jitao
    NEUROUROLOGY AND URODYNAMICS, 2019, 38 (01) : 22 - 30
  • [27] Comparison of the efficacy and safety of onabotulinum toxin A and mirabegron for overactive bladder in elderly patients
    Karakeci, A.
    Keles, A.
    Onur, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (01) : 350 - 356
  • [28] Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
    Xu, Yankai
    Liu, Ruihua
    Liu, Chu
    Cui, Yuanshan
    Gao, Zhenli
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2017, 21 (03) : 212 - 219
  • [29] Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms
    Wu, Tsung-Hsien
    Shen, Yuan-Chi
    Lee, Wei-Chia
    Wang, Hung-Jen
    Chuang, Yao-Chi
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (01) : 55 - 59
  • [30] The efficacy and tolerability of mirabegron, a beta 3 adrenoceptor agonist, in patients with symptoms of overactive bladder
    Thiagamoorthy, Ganesh
    Kotes, Stephanie
    Zacche, Martino
    Cardozo, Linda
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 38 - 46
12345